PARP1 and ovarian cancer: Our data in SKOV3 and CAOV3 HR-proficient ovarian cancer cell lines showed that ATO combination with all three PARP inhibitors, especially olaparib and fluazolepali, led to significant accumulation of DNA damage as well as cell apoptosis, promoting cancer cell death.